کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2941348 | 1177066 | 2009 | 8 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention : Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention : Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group](/preview/png/2941348.png)
ObjectivesThis study compares outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients undergoing saphenous vein graft (SVG) intervention.BackgroundThe safety and efficacy of DES in patients undergoing SVG intervention is controversial.MethodsThe STENT (Strategic Transcatheter Evaluation of New Therapies) registry is a multicenter U.S. registry evaluating outcomes with DES. Our study population includes patients undergoing PCI of SVG lesions with DES (n = 785) or BMS (n = 343) who completed 9-month or 2-year follow-up. Outcomes were adjusted with propensity analyses.ResultsThe DES patients had fewer emergent procedures but had smaller vessels and longer lesions. The DES patients had less death or myocardial infarction at 9 months (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.33 to 0.83, p = 0.006) and less death at 2 years (HR: 0.60, 95% CI: 0.36 to 0.98, p = 0.041). Target vessel revascularization (TVR) was less with DES at 9 months (7.2% vs. 10.0%, HR: 0.36, 95% CI: 0.22 to 0.61, p < 0.001) but was no different by 2 years (18.3% vs. 16.9%, p = 0.86), although adjusted TVR rates were lower (HR: 0.60, 95% CI: 0.40 to 0.90, p = 0.014). The DES reduced TVR at 9 months in SVG lesions with diameter <3.5 mm (8.0% vs. 17.2%, p = 0.013) but not ≥3.5 mm (6.0% vs. 6.6%, p = 0.74).ConclusionsTreatment of SVG lesions with DES vs. BMS is effective in reducing TVR at 9 months, although most of this advantage is lost at 2 years. The DES seem safe with less death or myocardial infarction, although selection bias might have affected these results. Our data suggest that DES might have short-term advantages over BMS in SVG lesions with diameter <3.5 mm.
Journal: JACC: Cardiovascular Interventions - Volume 2, Issue 11, November 2009, Pages 1105–1112